scholarly journals Microevolution infimHGene of Mucosa-Associated Escherichia coli Strains Isolated from Pediatric Patients with Inflammatory Bowel Disease

2012 ◽  
Vol 80 (4) ◽  
pp. 1408-1417 ◽  
Author(s):  
Valerio Iebba ◽  
Maria Pia Conte ◽  
Maria Stefania Lepanto ◽  
Giovanni Di Nardo ◽  
Floriana Santangelo ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Environmental Changes ◽  
Mucosal Inflammation ◽  
Content Type ◽  
E Coli ◽  
Inflammatory Bowel ◽  
Tract Infections

ABSTRACTSeveral studies reported increased numbers of mucosa-associatedEscherichia colistrains in patients with inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC). The majority ofE. colistrains possess type 1 fimbriae, whose tip fibrillum protein, FimH, naturally undergoes amino acid replacements, an important process in the adaptation of commensalE. colistrains to environmental changes, like those observed in IBD and urinary tract infections. In this study, we analyzed mutational patterns in thefimHgene of 52 mucosa-associatedE. colistrains isolated from IBD and non-IBD pediatric patients, in order to investigate microevolution of this genetic trait. FimH-positive strains were also phylogenetically typed and tested for their adhesive ability on Caco-2 cells. Specific FimH alleles for each grouping feature were found. Mutations G66S and V27A were related to CD, while mutations A242V, V163A, and T74I were attributed to UC. Otherwise, the G66S, N70S, and S78N mutations were specifically attributed to B2/D phylogroups. The N70S and A119V mutations were related to adhesiveE. colistrains. Phylogroup B2, adhesive, and IBDE. colistrains showed a higher site substitution rate (SSR) in thefimHgene, together with a higher number of mutations. The degree of naïve mucosal inflammation was related to specific FimH alleles. Moreover, we could suggest that the V27A mutation is pathoadaptive for the CD intestinal habitat, while we could also suggest that both the N70S and S78N mutations are related to the more virulentE. coliB2 phylogroup. In conclusion, we found some FimH variants that seem to be more involved than others in the evolution of IBD pathogenesis.

MICROBIAL SHIFTS ARE ASSOCIATED WITH PATIENT-REPORTED SYMPTOMS IRRESPECTIVE OF MUCOSAL INFLAMMATION IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE

2021 ◽  
Vol 160 (3) ◽  
pp. S55-S56
Author(s):  
Jennifer Hellmann ◽  
Allison Ta ◽  
David Haslam ◽  
Kathleen Lake ◽  
Ramona Bezold ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Mucosal Inflammation ◽  
Patient Reported ◽  
Inflammatory Bowel

scholarly journals Escherichia coliPathobionts Associated with Inflammatory Bowel Disease

2019 ◽  
Vol 32 (2) ◽  
Author(s):  
Hengameh Chloé Mirsepasi-Lauridsen ◽  
Bruce Andrew Vallance ◽  
Karen Angeliki Krogfelt ◽  
Andreas Munk Petersen
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cell Activation ◽  
Immune Cell ◽  
Intestinal Biopsy ◽  
Content Type ◽  
E Coli ◽  
Immune Cell Activation ◽  
Facilitative Role ◽  
Inflammatory Bowel

SUMMARYGut bacteria play a key role in initiating and maintaining the inflammatory process in the gut tissues of inflammatory bowel disease (IBD) patients, by supplying antigens or other stimulatory factors that trigger immune cell activation. Changes in the composition of the intestinal microbiota in IBD patients compared to that in healthy controls and a reduced diversity of intestinal microbial species are linked to the pathogenesis of IBD. Adherent invasiveEscherichia coli(AIEC) has been linked to Crohn’s disease (CD) patients, while diffusely adherentE. coli(DAEC) has been associated with ulcerative colitis (UC). Bacteriological analysis of intestinal biopsy specimens and fecal samples from IBD patients shows an increased number ofE. colistrains belonging to the B2 phylogenetic group, which are typically known as extraintestinal pathogenicE. coli(ExPEC). Results from studies of both cell cultures and animal models reveal pathogenic features of theseE. colipathobionts, which may link them to IBD pathogenesis. This suggests that IBD-associatedE. colistrains play a facilitative role during IBD flares. In this review, we explain IBD-associatedE. coliand its role in IBD pathogenesis.

Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease

2012 ◽  
Vol 18 (5) ◽  
pp. 913-924 ◽  
Author(s):  
Anna Negroni ◽  
Manuela Costanzo ◽  
Roberta Vitali ◽  
Fabiana Superti ◽  
Lucia Bertuccini ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Inflammatory Bowel

Dominant genotypes in mucosa-associated Escherichia coli strains from pediatric patients with inflammatory bowel disease

2009 ◽  
Vol 15 (5) ◽  
pp. 661-672 ◽  
Author(s):  
Serena Schippa ◽  
Maria Pia Conte ◽  
Osvaldo Borrelli ◽  
Valerio Iebba ◽  
Marta Aleandri ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Inflammatory Bowel

A potential role of Escherichia coli pathobionts in the pathogenesis of pediatric inflammatory bowel disease

2012 ◽  
Vol 58 (4) ◽  
pp. 426-432 ◽  
Author(s):  
Serena Schippa ◽  
Valerio Iebba ◽  
Valentina Totino ◽  
Floriana Santangelo ◽  
Mariastefania Lepanto ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Gene Sequence ◽  
Sequence Similarity ◽  
Genomic Analysis ◽  
Neuraminidase Treatment ◽  
E Coli ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel

Through genomic analysis of mucosa-associated Escherichia coli strains, we found a close genetic association among isolates from pediatric inflammatory bowel disease (IBD) patients. A specific E. coli pathovar, adherent–invasive E. coli (AIEC), was found in Crohn’s disease (CD) adult patients — this pathovar has enhanced adhesive and invasive properties, mainly due to the mannose-bonding FimH protein. We aimed to characterize 52 mucosa-associated E. coli strains isolated from pediatric IBD and non-IBD patients. Eleven E. coli strains, showing a strong similarity in fimH gene sequence to that of E. coli AIEC LF82, were characterized for fimH gene sequence, genomic profiling, adhesive and invasive ability, and phylogrouping. The results were compared with E. coli strains AIEC LF82 and MG1655. The 11 E. coli isolates showed 82.4% ± 1.4% fimH sequence similarity and 80.6% ± 1.3% genomic similarity to strain AIEC LF82. All these strains harbored V27A and S78N FimH mutations, as found in LF82. Nine of them belonged to the more virulent B2 and D phylogroups. Neuraminidase treatment, mimicking inflamed mucosa, enhanced adhesion of all 11 strains by 3.5-fold, but none showed invasion ability. It could be argued that the 11 selected strains could be a branch of an E. coli subpopulation (pathobionts), that could take advantage in an inflamed context because of a suitable genomic and (or) genetic backdrop.

W1188 Dominant Genotypes in Mucosa-Associated Escherichia coli Strains from Pediatric Patients with Inflammatory Bowel Disease

2008 ◽  
Vol 134 (4) ◽  
pp. A-651
Author(s):  
Valerio Iebba ◽  
Maria Pia Conte ◽  
Serena Schippa ◽  
Marta Aleandri ◽  
Catia Longhi ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Inflammatory Bowel

Nutritional status and food intake in pediatric patients with inflammatory bowel disease at diagnosis significantly differs from healthy controls

2019 ◽  
Vol 178 (10) ◽  
pp. 1519-1527 ◽  
Author(s):  
Sara Sila ◽  
Ivana Trivić ◽  
Ana Močić Pavić ◽  
Tena Niseteo ◽  
Sanja Kolaček ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Food Intake ◽  
Nutritional Status ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Healthy Controls ◽  
Inflammatory Bowel

scholarly journals Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study

2021 ◽  
Vol 10 (14) ◽  
pp. 3177
Author(s):  
Edyta Szymanska ◽  
Maciej Dadalski ◽  
Joanna Sieczkowska-Golub ◽  
Dorota Jarzebicka ◽  
Monika Meglicka ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Case Control Study ◽  
Case Control ◽  
Chi Square ◽  
Infusion Reactions ◽  
Inflammatory Bowel ◽  
The Difference ◽  
Control Study

Background: Infusion reactions (IRs) are the most common adverse events (AEs) of infliximab (IFX) treatment in patients with inflammatory bowel disease (IBD). Prophylactic premedication (PM) with corticosteroids or antihistamines prior to IFX infusions has been used in clinical practice, but its efficacy is not known. The aim of this study was to assess the influence of steroid PM on IR incidence in pediatric patients with IBD receiving IFX. Methods: We performed a case–control study that included pediatric patients with IBD receiving IFX. Patients were divided into four subgroups according to the agent and PM they received: Remicade (original drug) + PM, and two biosimilars—Reshma +/− PM, and Flixabi—PM. At our site, until 2018, PM with steroids was used as a part of standard IFX infusion (PM+); however, since then, this method has no longer been administered (PM−). IRs were divided into mild/severe reactions. Differences between subgroups were assessed with the appropriate chi-square test. Multivariate logistic regression was used to assess associations between PM and IR incidence, correcting for co-medication usage. Results: There were 105 children (55 PM+, 44 male, mean age 15 years) included in the study who received 1276 infusions. There was no difference between the PM+ and PM− subgroups, either in incidence of IR (18.2% vs. 16.0% of patients, p > 0.05) or in percentage of infusions followed by IR (2.02% vs. 1.02% of infusions, p > 0.5). The OR of developing IR when using PM was 0.34, and the difference in IRs ratio in PM+ and PM− patients was not statistically significant (95% CI, 0.034–1.9). There were 11/18 (61.1%) severe IRs (anaphylactic shock) reported in all patients (both PM+ and PM−). Conclusion: At our site, the incidence of IR was low, and PM did not decrease the incidence of IR in pediatric patients with IBD receiving IFX. These results indicate that PM with steroids should not be a standard part of IFX infusion to prevent IR.

Diagnostic Medical Radiation in Pediatric Patients With Inflammatory Bowel Disease

2011 ◽  
Vol 53 (5) ◽  
pp. 502-506 ◽  
Author(s):  
Jeannie S. Huang ◽  
Allison Tobin ◽  
Lee Harvey ◽  
Thomas R. Nelson
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Medical Radiation ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document